HZNP
Horizon Pharma (HZNP) Shareholders Approve Vidara Therapeutics Purchase
Horizon Pharma (Nasdaq: HZNP) announced that at its Special Meeting of Stockholders held today, proposals related to Horizon's acquisition of Vidara Therapeutics International plc were approved by Horizon's stockholders.
As previously announced, on March 18, 2014, Horizon Pharma, Inc. ("Horizon"), Vidara Therapeutics Holdings LLC, Vidara Therapeutics International plc, an Irish public limited company ("Vidara"), Hamilton Holdings (USA), Inc., an indirect wholly-owned subsidiary of Vidara ("U.S. HoldCo"), and Hamilton Merger Sub, Inc., a wholly-owned subsidiary of U.S. HoldCo ("Merger Sub"), entered into a Transaction Agreement and Plan of Merger (the "Merger Agreement"). The Merger Agreement provides that, upon the terms and subject to the conditions set forth in the Merger Agreement, Merger Sub will merge with and into Horizon, with Horizon continuing as the surviving corporation and as a wholly-owned, indirect subsidiary of Vidara (the "Merger"), with Vidara changing its name to Horizon Pharma Public Limited Company, or plc ("New Horizon").
Horizon's stockholder approval satisfies certain closing conditions related to the Merger. The Merger remains subject to certain other customary closing conditions and approvals including the substitute listing of New Horizon's ordinary shares on the NASDAQ Stock Market. Horizon expects the closing to occur on September 19th after satisfaction of the remaining closing conditions.
«Después de nada, o después de todo/ supe que todo no era más que nada.»